Key facts
- Tethis’s last known valuation is $22.9M (Jul 2010).
- It has raised $19.7M; the latest was Later Stage VC ($15.6M) in Jan 2025.
- Notable investors include Indaco Venture Partners, ENEA Tech Biomedical, Genextra, Horizon 2020, INNOVIT (San Francisco) — 6 tracked in total.
- Tethis has filed 8 Form Ds with the SEC since 2013, most recently Feb 2018 ($3.9M sold to 75 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Tethis
- ·The full record, as it builds
Funding rounds
No funding rounds for Tethis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tethis
Developer of a smart diagnostic device designed to create a diversified range of potential applications in diagnosis, theragnostic, and drug discovery. The company's device permits circulating tumor cell diagnostics, through liquid biopsy using a total capture approach that does not require pre-enrichment and provides tools to support personalized medicine and targeted therapy in clinical settings, enabling healthcare providers with early diagnosis of cancer diseases, longitudinal studies, and residual minimal disease as a prognostic of possible recurrences.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2004
- Employees
- 33
- Website
- tethis-lab.com/
- Ownership
- Privately Held (backing)
Tethis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tethis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tethis in its N-PORT filings yet. We sweep new filings monthly.